Iwona Lugowska retweetledi
Iwona Lugowska
30 posts

Iwona Lugowska
@ILugowska
Plenipotentiary Director for the International Affair, Head of the Early Phase Clinical Trials Unit and Precision Oncology in National Institute of Oncology.
Warsaw, Poland Katılım Ekim 2021
25 Takip Edilen86 Takipçiler
Iwona Lugowska retweetledi

🚨 Only 1 day left! The #CCI4EU Sixth Online Course on Data Sharing & Exchange is happening tomorrow—15 April, 13:00–17:30 CEST!
Learn how to handle health data ethically, securely & efficiently.
🔗 Register now: #eso-desc" target="_blank" rel="nofollow noopener">e-eso.net/courses/25CC6#…
#CancerResearch #FAIRdata #DataSharing
English
Iwona Lugowska retweetledi

📸 The #OECI Experts’ Consensus Conference is underway!
OECI Vice-President @ILugowska opened the event in Brussels, emphasizing the need for a shared vision in Accreditation & Designation in cancer care.
#CancerCare #CancerResearch #QualityStandards

English
Iwona Lugowska retweetledi

📸 @ILugowska and the panelists during the session “From Diagnosis to Treatment – Best Practices and New Frontiers” at the #HADEA conference on #WorldCancerDay!

English
Iwona Lugowska retweetledi
Iwona Lugowska retweetledi

Save the date! #CCI4EU is announcing its second online course on Clinical Trials and Clinical Research, which will take place on 15 October 2024 from 13.30 - 16:30 (CEST).
➡️ To learn more and access the course, click here: e-eso.net/courses/24C2a
English
Iwona Lugowska retweetledi

#ESMO23: Meet the editors of the ESMO Handbooks of Supportive & #PalliativeCare & Cancer in Adolescents and Young Adults, Ivana Bozovic-Spasojevic & Giannis Mountzios ⏰ 23/10, 10:00 CEST ESMO Member Lounge
ow.ly/is2f50PZrZ9
#ESMObooks #AYACancer #supponc #pallonc

English
Iwona Lugowska retweetledi

ESMO E-Learning: Prognostic and Predictive #Biomarkers in #HeadandNeckCancer by Lisa Licitra, @drsalvoalfieri, @BubiSilvi & Simone Rota. ESMO Members can take the CME test and receive 1 ESMO-MORA point.
ow.ly/gL3P50Pnqop
#hncsm

English
Iwona Lugowska retweetledi

The latest ESMO Guidelines webinar on #ovariancancer is now available on-demand on OncologyPRO. Access the resources with your free ESMO account and learn how these recommendations can assist you in your daily practice 👉 ow.ly/6xu850Pntlq
@CoquardRay @bpellegrino89 #GynCSM

English
Iwona Lugowska retweetledi

📢 The updated ESMO Handbook of Nutrition and Cancer (2nd ed.) This fully-revised, peer-reviewed publication looks into many relevant topics & includes two new chapters on developing areas of interest.
PDF, eReaders & Kindle format. ow.ly/jxeE50P9jTi
#ESMObooks @ILugowska
English

Dr Paulina Jagodzińska-Mucha laureatką II miejsca za najlepszą pracę doktorska @NIO_PIB 2022-2023 gratulacje @ILugowska @hanicahanica

Polski
Iwona Lugowska retweetledi

‘‘Decision making should not only be viewed as the consequence of available prognostic information. The decisions patients make (e.g. to start, withhold or discontinue anticancer therapy) may themselves have an impact on future prognosis.’’
True for QoL too, not only survival!
ESMO - Eur. Oncology@myESMO
📢 Prognostic evaluation in patients with #advancedcancer in the last months of life: ESMO Clinical Practice Guideline. Prognostication and communication algorithm also included. ow.ly/tifo50NFMFG #PallOnc @ESMO_Open @curijoey @s_moine
English
Iwona Lugowska retweetledi

The ESMO Virtual Mentorship Programme offers ESMO Members under 40 the opportunity to develop their skills, knowledge & experience to progress in their career w/ a 1:1 mentorship.
👇Apply now, deadline 16 April 2023
ow.ly/CTqU50NAOTb
#ESMOYOC @matteolambe

English
Iwona Lugowska retweetledi

Really appreciated this #ESMOSarcomaAndRareCancers23 session dedicated to Young Oncologists career in #rarecancers challenges and opportunities @WTapMD @ILugowska @BenWestphalen @DrLizConnolly @pawel_sobczuk

English
Iwona Lugowska retweetledi

Nowe badanie ANNASARC dla chorych na mięsaki tkanek miękkich, u których wystąpiła progresja choroby w czasie leczenia co najmniej 1. linią chemioterapii z powodu choroby nieoperacyjnej lub przerzutowej @AgencjaBadanMed @NIO_PIB @sarcoma_pl @moleculinbio @OnkologiaPolska

Polski
Iwona Lugowska retweetledi

Very interesting start of #ENA2022 on the role of ctDNA in clinical trials. Tests, endpoints, impact on patients’ QoL etc. & critical discussions on RECIST.Nice talk also from @MIgnatiadis on line. Modern gender imbalance of the panel of experts this morning @EORTC @lillian_siu

English
Iwona Lugowska retweetledi

New: ESMO Handbook of Cancer in Adolescents & Young Adults: focusing on all aspects on #AYAoncology including diagnosis, treatment, psychosocial aspects and rehabilitation.
ow.ly/2JPj50KGfAe
#ayacsm #AYACancer @NivenMehra @g_mountzios

English
Iwona Lugowska retweetledi

📢@EORTC Past Presidents Forum, with long-standing friends including
👉Martine Piccart, President 2006-2009 & ECO President 2014-2015
👉@Winette_vdGraaf, EORTC President & ECO Board Member
👉@jeanyvesblay, EORTC President 2009 - 2012
#EORTC60


English
Iwona Lugowska retweetledi

#ESMO22 Highlights - DeFi: A Phase 3, Randomised Controlled Trial of Nirogacestat Versus Placebo for Progressing #DesmoidTumours with Bernd Kasper.
ow.ly/ki4K50KG8x5
#rarecancer
English
Iwona Lugowska retweetledi

#ESMO22: 3️⃣💐reasons to celebrate 🥂 with our beloved Educ Publications working group:
1. HB of Supportive@palliative care is out
2. HB of adolescent/young adults wt cancer ready to come out!
3. Best part: @myESMO brings us together, creating bonds that last forever! #some


Paris, France 🇫🇷 English
